So, here's what happened to Lantern Pharma Inc. (LTRN) over the last few days. Imagine you're an investor, you check your portfolio on a quiet Friday, and you see one of your biotech holdings is down... 46%. That's not a dip; that's a cliff. The reason? A report, apparently from a third party, claimed the company's CEO, Panna Sharma, had stepped down.

By Monday morning, the stock was trying to claw its way back, up over 11% in premarket trading. Why the whiplash? Because Lantern Pharma came out swinging over the weekend, calling the whole thing nonsense.

The company didn't mince words. In a statement issued late Friday, it labeled the information "fabricated." More specifically, it said the claim that Sharma had resigned as President and CEO was "false, entirely without basis, and appears designed to mislead investors." They confirmed he's still very much in charge and on the job.

This wasn't just a company spokesperson putting out a fire. The Board of Directors chimed in, too. Chairman Donald Jeff Keyser said the board has "full confidence" in Sharma's leadership and clarified they have no plans for a change at the top. They also dropped an interesting tidbit: they're looking into where this article came from and whether there was any "coordinated trading activity" around it. That's corporate-speak for "we're checking if someone tried to manipulate our stock price."

All this drama completely overshadowed some actual, positive company news from Friday. Lantern Pharma and its partner, Starlight Therapeutics, announced that the U.S. Food and Drug Administration cleared an Investigational New Drug (IND) application. This clearance is for a planned Phase 1 pediatric clinical trial of a drug candidate called STAR-001. In the normal world of a small biotech, that's a meaningful regulatory milestone. In the world of a 46% single-day crash based on a fake CEO story, it gets lost in the noise.

Investors are now pivoting to the next event: the company's fourth quarter 2025 earnings call, scheduled for Monday.

Let's look at the technical picture, which explains why a 11% premarket bounce still leaves the stock in a deep hole. The numbers are stark. As of this move, Lantern Pharma is trading 47.1% below its 20-day simple moving average and a whopping 59.1% below its 100-day average. That paints a very bearish trend across multiple timeframes.

Over the past year, shares are down 68.36%. They are hovering much closer to the 52-week low of $1.11 than the high of $5.74. The Relative Strength Index (RSI) is at 14.35, which is deep into "oversold" territory (typically anything below 30 is considered oversold). The MACD, another momentum indicator, is also in negative territory.

For the chart watchers, key resistance is seen at the $2.50 level, while key support sits at $1.00.

So, the Monday morning rebound is a relief rally—a bounce after an extreme, news-driven sell-off. The company has forcefully denied the catalyst for the crash. But the technical damage from Friday's plunge is severe, and the stock's longer-term trend remains decidedly negative. The immediate question is whether the earnings call can shift focus back to the company's actual business and clinical progress, or if the shadow of last week's volatility will linger.